New strategies in lung cancer: Translating immunotherapy into clinical practice

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1067-1073

  Forde, Patrick M ^a   Kelly, Ronan J ^a   Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELAGENPUMATUCEL L; BMS 936559; CANCER VACCINE; IPILIMUMAB; MELANOMA ANTIGEN 3 VACCINE; MK 3475; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR VACCINE; TECEMOTIDE; TERGENPUMATUCEL L; TG 4010; TG 4010 VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CELLULAR IMMUNITY; CHEMORADIOTHERAPY; CLINICAL PRACTICE; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG FATALITY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 84895812969     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0731     Document Type: Article

References (63)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127:2893-917.
2. Available from: www.seer.cancer.gov.
3. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-54.
4. Carney DN. Lung cancer-time to move on from chemotherapy.NEngl J Med 2002;346:126-8.
5. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30: 2055-62.
6. Zinner R, Ross HJ, Weaver R, Govindan R, Holden VR, Chowhan NM, et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small cell lung cancer. Presented at: American Society of Clinical Oncology Annual Meeting. May 31-June 3, 2013, Chicago, IL.
7. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-902.
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
10. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34.
11. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
12. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
13. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39.
14. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013;39:61-73.
15. Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 2013;73:2381-8.
16. Remakus S, Sigal LJ. Memory CD8+ T cell protection. Adv Exp Med Biol 2013;785:77-86.
17. Wang YC, Sung WW, Wu TC, Wang L, Chien WP, Cheng YW, et al. Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One 2012;7:e39525.
18. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGFb IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010;107:15535-40.
19. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, et al. PGE(2) contributes to TGF-b induced T regulatory cell function in human nonsmall cell lung cancer. Am J Transl Res 2010;2:356-67.
20. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-44.
21. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14: 5220-7.
22. Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K Tumor-infiltrating. Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5: 585-90.
23. Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang L, et al. A polymorphic-844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res 2011;17: 5991-9.
24. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11:8055-62.
25. Nirschl CJ, Drake CG. Molecular pathways: co-expression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013;19: 4917-24.
26. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as firstline treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-54.
27. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
28. Butts CA, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski MJ, et al. START: a phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. Presented at: American Society of Clinical Oncology Annual Meeting, May 31-June 4, 2013, Chicago, IL.
29. Available from: www.clinicaltrials.gov: NCT identifier - NCT00480025.
30. Available from: www.clinicaltrials.gov: NCT01444118.
31. Giaccone G, Bazhenova L, Nemunaitis J, Juhasz E, Ramlau R, van den HeuvelMM, et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small-cell lung cancer (NSCLC). Presented at: 2013 European Cancer Conference; September 27-October 1, 2013, Amsterdam, The Netherlands.
32. Available from: www.clinicaltrials.gov: NCT01383148.
33. Woenckhaus M, Merk J, Stoehr R, Schaeper F, Gaumann A, Wiebe K, et al. Prognostic value of FHIT, CTNNB1, andMUC1expression in nonsmall cell lung cancer. Hum Pathol 2008;39:126-36.
34. Rossi A. Is vaccine therapy a renewed strategic approach for nonsmall-cell lung cancer therapy? Expert Rev Vaccines 2013;12:5-7.
35. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Souliéres D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23:6674-81.
36. Butts C, Maksymiuk A, Goss G, Souliéres D, Marshall E, Cormier Y, et al. Updated survival analysis in patients with stage IIIB or IV nonsmall-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137:1337-42.
37. Available from: www.clincialtrials.gov: NCT01015443.
38. Available from: www.clinicaltrials.gov: NCT00828009.
39. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013;31:2396-403.
40. Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31: 2388-95.
41. Tyagi P, Mirakhur B, MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10:371-4.
42. Gonzalez Marinello GM, Santos ES, Raez LE. Epidermal growth factor vaccine in non-small-cell lung cancer. Expert Rev Anticancer Ther 2012;12:439-45.
43. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008;26:1452-8.
44. Malkoski SP, Haeger SM, Cleaver TG, Rodriguez KJ, Li H, Lu SL, et al. Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. Clin Cancer Res 2012;18: 2173-83.
45. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, et al. Phase II study of belagenpumatucel-L, a transforming growth factor b-2 antisense gene-modified allogeneic tumor cell vaccine in non-small cell lung cancer. J Clin Oncol 2006; 24:4721-30.
46. Morris JC, Rossi GR, Harold N, Tennant L, Ramsay WJ, Wahanian NN, et al. Potential chemo-sensitization effect of tergenpumatucel-L in treated patients with advanced non-small-cell lung cancer. Presented at: 2013 ASCO Annual Meeting; May 31-June 4 2013, Chicago, IL.
47. Available from: www.clinicaltrials.gov: NCT01774578.
48. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Lévy E, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008;3:735-44.
49. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
50. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
51. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97.
52. Available from: www.clinicaltrials.gov: NCT01285609.
53. Brahmer JR, Horn L, Antonia SJ, Spigel DR, Gandhi L, Sequist LV, et al. Survival and long-term follow-up of the phase I trial of nivolumab in patients with previously treated advanced non-small-cell lung cancer. Presented at: 2013 ASCO Annual Meeting; May 31-June 4 2013, Chicago, IL.
54. Topalian SL, Sznol M, Brahmer JR, McDermott DF, Smith DC, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial. Presented at: 2013 ASCO Annual Meeting; May 31-June 4 2013, Chicago, IL.
55. Available from: www.clinicaltrials.gov: NCT01673867.
56. Available from: www.clinicaltrials.gov: NCT01642004.
57. Rizvi NA, Antonia SJ, Chow LQ, Brahmer JR, Juergens RA, Borghaei H, et al. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy in chemotherapy-naive non-small cell lung cancer patients. Presented at: 2013 ASCO Annual Meeting; May 31-June 4 2013, Chicago, IL.
58. Available from: www.clinicaltrials.gov: NCT01454102.
59. Patnaik A, Kang SP, Tolcher AW, Rasco DW, Papadopoulos KP, Beeram M, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Presented at: ASCO Annual Meeting Chicago, IL, June 1-5, 2012.
60. Garon EB, Balmanoukian A, Hamid O, Hui R, Gandhi L, Leighl N, et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small-cell lung cancer (NSCLC). Presented at: 15th World Conference on Lung Cancer; October 27-30, 2013, Sydney, Australia.
61. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
62. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366: 2455-2465.
63. Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): Additional analysis from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Presented at: 2013 European Cancer Conference; September 27-October 1, 2013, Amsterdam, The Netherlands.